JAK1 inhibition and Anti-PD1 therapy enhance outcomes in advanced lung cancer

JAK1 inhibition and Anti-PD1 therapy enhance outcomes in advanced lung cancer
Adding an anti-inflammatory drug to anti-PD1 checkpoint inhibitor immunotherapy has shown great promise as a new strategy against advanced lung cancer, based on...
Adding an anti-inflammatory drug to anti-PD1 checkpoint inhibitor immunotherapy has shown great promise as a new strategy against advanced lung cancer, based on... Read More



Related Stories

See All